Process for the preparation of ccr-2 antagonists
    81.
    发明申请
    Process for the preparation of ccr-2 antagonists 有权
    制备ccr-2拮抗剂的方法

    公开(公告)号:US20070135475A1

    公开(公告)日:2007-06-14

    申请号:US10577587

    申请日:2004-10-25

    IPC分类号: A61K31/4745 C07D471/02

    摘要: The present invention provides an efficient synthesis for the preparation of ((1R,3S)-3-isopropyl-3-{[3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]carbonyl}cyclopentyl)[(3S,4S)-3-m ethoxytetrahydro-2H-pyran-4-yl]amine and its succinate salt. The present invention additionally provides an efficient syntheses for the preparation of intermediates (3R)-3-methoxytetrahydro-4H-pyran-4-one; (1S,4S)-4-(2,5-dimethyl-1H-pyrrol-1-yl)-1-isopropylcyclopent-2-ene-1-carboxylic acid; and 3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,6-naphthyridine; and for the preparation of the precursor (3S,4S)-N-((1S,4S)-4-isopropyl-4-{[3-(tri-fluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]carbonyl}cyclopent-2-en-1-yl)-3-methoxytetrahydro-2H-pyran-4-amine. The invention additionally resides in the superior properties of the succinate salt of ((1R,3S)-3-isopropyl-3-1{[3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]carbonyl}cyclopentyl)[(3S,4S)-3-methoxytetrahydro-2H-pyran-4-yl]amine.

    摘要翻译: 本发明提供了制备((1R,3S)-3-异丙基-3 - {[3-(三氟甲基)-7,8-二氢-1,6-二氮杂萘-6(5H) ]羰基}环戊基)[(3S,4S)-3-甲氧基四氢-2H-吡喃-4-基]胺及其琥珀酸盐。 本发明另外提供了制备中间体(3R)-3-甲氧基四氢-4H-吡喃-4-酮的有效合成方法; (1S,4S)-4-(2,5-二甲基-1H-吡咯-1-基)-1-异丙基环戊-2-烯-1-羧酸; 和3-(三氟甲基)-5,6,7,8-四氢-1,6-萘啶; 制备前体(3S,4S)-N - ((1S,4S)-4-异丙基-4 - {[3-(三氟甲基)-7,8-二氢-1,6-萘啶-2-基] (5H) - 基]羰基}环戊-2-烯-1-基)-3-甲氧基四氢-2H-吡喃-4-胺。 本发明另外存在((1R,3S)-3-异丙基-3-1 {[3-(三氟甲基)-7,8-二氢-1,6-二氮杂萘-6(5H))的琥珀酸盐的优异性质 ) - 基]羰基}环戊基)[(3S,4S)-3-甲氧基四氢-2H-吡喃-4-基]胺。

    DERIVATIVES OF RESIQUIMOD
    86.
    发明申请

    公开(公告)号:US20200207757A1

    公开(公告)日:2020-07-02

    申请号:US16612216

    申请日:2018-05-18

    发明人: Lihu Yang

    IPC分类号: C07D471/04

    摘要: A deuterated compound having structural formula I or a pharmaceutically acceptable salt thereof: Values and example values of the variable in formula (I) are disclosed herein. Also disclosed are the use of compounds of formula (I) in the methods of treating a disease selected from cancer, an autoimmune disease, and an infectious disease, and methods of enhancing an immune response to an antigen.